rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GSK
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      GSK Marks Second Lung Cancer Drug Approval This Year
      12h agoBenzingaGSK
      FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
      13h agoYahoo FinanceGSK
      Barclays Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)

      Detailed price information for Gsk Plc ADR (GSK-N) from The Globe and Mail including charting and trades.

      19h agoThe Globe and MailGSK
      GSK Receives FDA Accelerated Approval for Nelkarmi in Previously Treated ALK-Positive Lung Cancer

      GSK plc (LSE:GSK) has received accelerated approval from the US Food and Drug Administration (FDA) for Nelkarmi (neladalkib), a targeted treatment for adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). The approval covers patients who have previously received alectinib as their only ALK tyrosine kinase inhibitor (TKI), or at least two prior ALK inhibitors and platinum-based chemotherapy, in the unresectable locally advanced or metastat

      19h agoYahoo FinanceGSK
      GSK Gets FDA Approval for New Lung-Cancer Drug

      GSK can now launch a new medicine in the U.S. for lung cancer, a move that bolsters its efforts to build a franchise in a disease that is the leading cause of cancer death.

      19h agoWSJGSK
      GSK CFO Points to Cancer Drugs to Bridge £3.4 Billion Sales Forecast Gap
      Nov 18Yahoo FinanceGSK
      FDA approves GSK’s Nelkarmi for pretreated ALK-positive lung cancer
      Nov 17Investing.comGSK
      US FDA approves GSK's second lung cancer drug from historic Nuvalent deal
      Nov 17ReutersGSK
      GSK cancer drug approved by US regulators
      Nov 17Financial TimesGSK
      GSK wins FDA approval for lung cancer drug Nelkarmi
      Nov 17Investing.comGSK
      GSK’s Potential Blockbuster Lung Cancer Drug Approved in US
      Nov 17BloombergGSK
      GSK at J.P. Morgan UK Leaders Conference: growth plan gains pace
      Nov 17Investing.comGSK
      GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms
      Nov 17Yahoo FinanceGSK
      GSK: 3 Key Takeaways for Long-Term Investors
      Nov 17Yahoo FinanceGSK
      GSK (LSE:GSK) Settles Key Vaccine Patent Case And Wins Broad Europe Injunction
      Nov 13Yahoo FinanceMRNAGSK
      Is GSK (LSE:GSK) A Bargain Following Its New Alamar Collaboration?
      Nov 13Yahoo FinanceGSK
      Deutsche Bank Remains a Hold on GlaxoSmithKline (GSK)

      Tipranks Press Release.

      Nov 11The Globe and MailGSK
      GSK falls Wednesday, underperforms market
      Nov 11MarketWatchGSK
      U.S. measles elimination status is at risk as regional WHO body holds annual meeting
      Nov 11Seeking AlphaGSK
      What GSK (LSE:GSK)'s Cancer And HIV Trial Wins Mean For Shareholders
      Nov 9Yahoo FinanceGSK
      Why Is GSK (LSE:GSK) Drawing Attention For New Cancer Data And Proteomics?
      Nov 9Yahoo FinanceGSK
      GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
      Nov 9Yahoo FinanceGSK
      GSK at Guggenheim healthcare conference: pushing long-acting biologics
      Nov 9Investing.comGSK
      The CEO job is hard enough to land once. HP's incoming chief has done it twice | Fortune

      Emma Walmsley will join an exclusive club of CEOs who’ve led two corporate giants.

      Nov 9FortuneGSKHPQ
      Should you buy shares in GSK?
      Nov 9The TimesGSK
      GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
      Nov 6ReutersMRNAGSK
      Why HP chose GSK chief Emma Walmsley as CEO | Fortune

      Ex-GSK chief Emma Walmsley was the first woman to run a major pharma company. Now she'll bring her transformation experience to hardware.

      Nov 6FortuneGSKHPQ
      Wisconsin reports measles-linked infant death (GSK:NYSE)
      Nov 6Seeking AlphaGSK
      GSK (LSE:GSK) Stock Still Looks Below Fair Value Following Jemperli Approval

      GSK plc has delivered strong multi year gains for shareholders, and the latest news around its cancer and specialty medicines raises a straightforward question for you as an investor. Is the current share price near £18.90 adequately supported by the drug maker's earnings power, or has sentiment moved ahead of what the income statement can justify? Over the past 3 years the stock has returned about 50.2%, which puts real weight on whether the underlying profits can sustain that kind of share...

      Nov 6Yahoo FinanceGSK
      Ex-GSK boss Emma Walmsley’s HP pay package could reach $60m
      Nov 5The TimesGSKHPQ
      HP Appoints Emma Walmsley as CEO, Concluding Executive Search
      Nov 4BloombergGSKHPQ
      Who is HP's new CEO Emma Walmsley?
      Nov 4ReutersMSFTGSKHPQ
      HP Taps Former GSK Executive Emma Walmsley as Next CEO

      HP said Walmsley, who was at the helm of drugmaker GSK from April 2017 until the end of 2025, will join the Palo Alto, Calif., company on Jan. 4.

      Nov 4WSJGSKHPQ
      HP names former GSK chief Emma Walmsley as CEO
      Nov 4ReutersGSKHPQ
      Ex-GSK boss Emma Walmsley takes top job at PC-maker HP
      Nov 4The TimesGSKHPQ
      Ex-GSK boss Dame Emma Walmsley takes top job at PC-maker HP
      Nov 4The TimesGSKHPQ
      HP Names Emma Walmsley as New CEO, Ending Monthlong Search

      HP Inc. named former GSK Plc chief executive officer Emma Walmsley as its new CEO, permanently filling the role after HP’s Enrique Lores departed earlier this year.

      Nov 4Yahoo FinanceGSK
      Brokers can’t agree on GSK shares but I’m watching its cancer pipeline

      Mark Hartley weighs up the case for GSK shares after noticing a large discrepancy in broker targets. But are they focusing on the right thing? The post Brokers can’t agree on GSK shares but I’m watching its cancer pipeline appeared first on The Twelfth Magpie.

      Nov 4Yahoo FinanceGSK
      Alamar Biosciences partners with GSK on proteomics study
      Nov 3Investing.comGSK
      Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
      Nov 3Yahoo FinanceGSK
      EnteroBiotix Appoints former GSK Chief Medical Officer Dr Murray Stewart to Board of Directors
      Nov 2MorningstarGSK
      GSK (LSE:GSK) Wins FDA Nod For Jemperli As ESMO Data Builds Oncology Case
      Nov 1Yahoo FinanceGSK
      Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
      Oct 30Yahoo FinanceGSKLLY
      GSK: What We Think of the Stock After Earnings
      Oct 30MorningstarGSK
      GSK Stock: The Gas Pedal Is Still Down, But Bumps Ahead (NYSE:GSK)

      GSK stock remains a Buy despite Q3 misses, with Specialty Medicines growth, pipeline momentum, valuation upside, and key risks to watch. See more here.

      Oct 30Seeking AlphaGSK
      GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
      Oct 29Yahoo FinanceMRNAGSK
      Jefferies downgrades GlaxoSmithKline stock rating on limited momentum
      Oct 29Investing.comGSK
      GSK (LSE:GSK) Shares Dropped, So What Is Behind The Latest Attention?
      Oct 29Yahoo FinanceGSK
      GSK (GSK) Q3 2026 Earnings Call Transcript
      Oct 28The Globe and MailGSK
      Glaxo: Q3 Earnings Snapshot
      Oct 28Yahoo FinanceGSK

      This is the newest page. Registered accounts read further back.